NOVAVAX INC Other Current Liabilities
NOVAVAX INC (NVAX) had Other Current Liabilities of $135.53 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Other Liabilities, Current $135.53M.
- 2026-03-31: Other Liabilities, Current $132.45M.
- 2025-12-31: Other Liabilities, Current $137.78M.
- 2025-09-30: Other Liabilities, Current $138.33M.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $135.53M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $132.45M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $137.78M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $138.33M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $132.53M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $142.03M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $219.60M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $281.71M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $242.81M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $242.10M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $861.41M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $861.96M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $749.19M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $858.38M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $930.05M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $160.50M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $34.16M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $31.27M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $36.06M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $3.64M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $9.89M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $2.39M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $8.86M 10-K · filed 2022-03-01 | $3.78M 10-K · filed 2021-03-01 |
| 2020-09-30 | $5.60M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $1.47M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $1.32M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $1.26M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $1.19M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $1.14M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $3.49M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $1.60M 10-K · filed 2020-03-11 | |
| 2018-09-30 | $1.57M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $1.53M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $1.50M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $7.75M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $1.39M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $1.36M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $1.35M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $1.06M 10-K · filed 2018-03-14 | |
| 2016-09-30 | $55.00K 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $73.00K 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $72.00K 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $3.01M 10-K · filed 2017-02-27 | $1.60M 10-K · filed 2016-02-29 |
| 2015-09-30 | $1.70M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $1.70M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $1.70M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $70.00K 10-K · filed 2016-02-29 | |
| 2013-12-31 | $379.00K 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |